| 2.03 0.21 (11.54%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.72 |
1-year : | 3.17 |
| Resists | First : | 2.32 |
Second : | 2.72 |
| Pivot price | 1.85  |
|||
| Supports | First : | 1.95 |
Second : | 1.72 |
| MAs | MA(5) : | 1.85 |
MA(20) : | 1.93 |
| MA(100) : | 2.05 |
MA(250) : | 2.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 35.4 |
D(3) : | 21.2 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 3.95 | Low : | 1.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SERA ] has closed It is unclear right now based on current values. 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.05 - 2.06 | 2.06 - 2.07 |
| Low: | 1.8 - 1.81 | 1.81 - 1.82 |
| Close: | 2.01 - 2.03 | 2.03 - 2.04 |
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Wed, 01 Jul 2026
Director Mark Christopher Capone files Form 3 for Sera Prognostics (SERA) - Stock Titan
Wed, 01 Jul 2026
Sera Prognostics, Inc. Class A Actuals & Estimates (NASDAQ:SERA) - TradingView
Tue, 30 Jun 2026
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
Tue, 30 Jun 2026
Sera Prognostics, Inc. Announces Appointment of Mark Capone to Board of Directors, Effective July 1, 2026 - marketscreener.com
Tue, 30 Jun 2026
Mark Capone appointed to Sera Prognostics board, joins Compensation Committee - TradingView
Tue, 30 Jun 2026
Veteran diagnostics leader Mark Capone joins Sera Prognostics (NASDAQ: SERA) board - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.748e+007 (%) |
| Held by Institutions | 11.5 (%) |
| Shares Short | 281 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.581e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -66 % |
| Return on Assets (ttm) | 857.1 % |
| Return on Equity (ttm) | -21.7 % |
| Qtrly Rev. Growth | 57000 % |
| Gross Profit (p.s.) | -67.24 |
| Sales Per Share | -42.11 |
| EBITDA (p.s.) | -115957 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.1 |
| Dividend | 0 |
| Forward Dividend | 265260 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|